Cisplatin exposure dysregulates pancreatic islet function in male mice

Lahari Basu,Kelsea S McKay,Myriam P Hoyeck,Lili Grieco-St-Pierre,Kayleigh RC Rick,Emilia Poleo-Giordani,Evgenia Fadzeyeva,Erin E Mulvihill,Jan A Mennigen,Jennifer E Bruin

DOI: https://doi.org/10.1101/2024.09.25.614996

2024-09-26

Abstract:Cancer survivors have an increased risk of developing new-onset Type 2 diabetes compared to the general population. Moreover, patients treated with cisplatin, a commonly used chemotherapeutic agent, are more likely to develop metabolic syndrome and Type 2 diabetes compared to age- and sex-matched controls. Insulin-secreting beta cells, located within pancreatic islets, are critical for maintaining glucose homeostasis, and dysregulated insulin secretion is central to Type 2 diabetes pathophysiology. Surprisingly, the impact of cisplatin treatment on pancreatic islets has not been reported. In this study, we aimed to determine if murine islet function is adversely affected by direct or systemic exposure to cisplatin. In vitro cisplatin exposure to male mouse islets profoundly dysregulated insulin release, reduced oxygen consumption, and altered the expression of genes related to insulin production, oxidative stress, and the Bcl-2 family. In vivo cisplatin exposure led to sustained hypoinsulinemia and hypoglycemia in male mice. Pancreas tissues from cisplatin-exposed male mice showed increased proinsulin accumulation and expression of DNA-damage markers in beta cells, but no change in average islet size or % insulin+ area per islet. Our data suggest both direct and systemic cisplatin exposure cause acute defects in insulin secretion and may have lasting effects on islet health in mice.

Molecular Biology